In CRC context, some studies demonstrated that oncogenic KRAS is able to reduce the expression of IFNγ targeted genes in KRASMUT tumor cells (HCT-116 cells with KRASG13D), including STAT1 and MHC-II. The gene discussed is IFNG; the disease is colorectal carcinoma.